GEXVal CTO to Present at CBI Annual Meeting 2025

株式會社GEXVal
October 17, 2025

GEXVal CTO to Present at Chemo-Bio Informatics Society (CBI) Annual Meeting 2025

GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that Chief Technology Officer Dr. Yusuke Nakayama will present “AI-Enhanced Data-Driven Drug Repurposing Platform: Graph Attention Autoencoder¹⁾ with Multi-Layered Multimodal Approach for Accelerated COVID-19 Therapeutic Discovery” at the 2025 Annual Conference of the Japanese Society for Bioinformatics.

[Event Overview]
Selected as an oral presentation, this talk will introduce GEXVal's proprietary AI platform that integrates Graph Neural Networks²⁾ and pharmacoinformatics technologies for drug repurposing—the discovery of new drug candidates and novel applications for existing pharmaceuticals.

**Presentation Details**

[About the Chem-Bio Informatics Society (CBI)]
The Chem-Bio Informatics Society (CBI), established in 1981, is an academic organization with over 40 years of established excellence, leading the convergence of chemistry, biology, and computational informatics.
In recent years, the application of AI and machine learning technologies to pharmaceutical development has become a central theme of the annual conference, with increasing presentations of industry-academia collaborative projects by pharmaceutical and biotechnology companies. Active discussions on translating fundamental research into social implementation make this conference a crucial platform for shaping next-generation life science innovation.

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

1), 2) About Graph Attention Autoencoder (GATE) and Graph Neural Networks (GNNs)
Graph Neural Networks (GNNs) are AI technologies that learn patterns from various "connections" in data. In particular, Graph Attention Network (GAT) is widely used in everyday services such as social media recommendations and logistics route optimization. Notably, Graph Attention Autoencoder (GATE), which GEXVal pioneered in drug discovery, has previously been limited to specific applications in life sciences, such as protein structure prediction. By innovatively applying GATE technology to the entire drug discovery process, GEXVal enables the discovery of novel therapeutic candidates that would otherwise remain unidentified through conventional methods.

有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com